Sbir topic 106: production of adjuvant mimics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00037
- Awardee
-
Adjuvax LLC UEI EGVNJG3GMEL7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $600,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35226, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $600,000 |
About this award
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total small business participation and will support research and development from August 2022 through August 2024. The prime contractor will perform all work within the United States to advance the goals of developing medical technologies and vaccines.
Quick answers
Who was awarded contract 75N93022C00037?
75N93022C00037 was awarded to Adjuvax LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 30, 2022.
How much is contract 75N93022C00037 worth?
The government has obligated $600,000 on 75N93022C00037.
Was contract 75N93022C00037 competed?
The extent of competition for 75N93022C00037 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award